Kazunori Tanizawa

机构：JCR Pharmaceuticals (Japan)

发表论文 29 篇 · 总被引 394 次 · h-index 8

代表论文

• Iduronate-2-sulfatase fused with anti-hTfR antibody, pabinafusp alfa, for MPS-II: A phase 2 trial in Brazil (2021 · Molecular Therapy · 被引 62)
• Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data (2021 · International Journal of Molecular Sciences · 被引 45)
• Treatment of Neuronopathic Mucopolysaccharidoses with Blood–Brain Barrier-Crossing Enzymes: Clinical Application of Receptor-Mediated Transcytosis (2022 · Pharmaceutics · 被引 31)
• Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid (2022 · Metabolic Brain Disease · 被引 21)
• Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report (2021 · JIMD Reports · 被引 19)
• α-L-iduronidase fused with humanized anti-human transferrin receptor antibody (lepunafusp alfa) for mucopolysaccharidosis type I: A phase 1/2 trial (2024 · Molecular Therapy · 被引 14)